<DOC>
	<DOCNO>NCT01343004</DOCNO>
	<brief_summary>The purpose study determine whether BA058 ( abaloparatide ) , parathyroid hormone-related peptide , effective preventing fracture postmenopausal woman severe osteoporosis risk fracture .</brief_summary>
	<brief_title>Study Evaluate Safety Efficacy BA058 ( Abaloparatide ) Prevention Fracture Postmenopausal Women</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , comparative Phase 3 , multicenter international study evaluate efficacy safety BA058 ( abaloparatide ) 80 µg prevention fracture otherwise healthy ambulatory postmenopausal woman severe osteoporosis .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>Healthy ambulatory postmenopausal ( ≥ 5 year ) woman 50 85 year age ( inclusive ) diagnosis osteoporosis The woman bone mineral density ( BMD ) T score ≤ 2.5 &gt; 5.0 lumbar spine hip ( femoral neck ) dual energy xray absorptiometry ( DXA ) radiological evidence 2 mild one moderate lumbar thoracic vertebral fracture , history low trauma forearm , humerus , sacral , pelvic , hip , femoral , tibial fracture within past 5 year . Postmenopausal woman older 65 meet fracture criterion T score ≤ 2.0 &gt; 5.0 may enrol . Women old 65 meet fracture criterion may also enrol T score ≤ 3.0 &gt; 5.0 Normal physical exam , vital sign , electrocardiogram ( ECG ) medical history Laboratory test within normal range include serum calcium , PTH ( 184 ) , serum phosphorus alkaline phosphatase History 4 mild moderate spine fracture severe fracture Abnormality spine hip would prohibit assessment bone mineral density ( BMD ) Unexplained elevation serum alkaline phosphatase , history bone disorder ( Paget 's disease ) diagnosis cancer within last 5 year ( exception basal cell squamous cancer skin ) History thyroid , parathyroid , adrenal disorder , malabsorptive syndrome chronic recurrent disease disturbance would interfere interpretation study data compromise safety patient Prior treatment parathyroid hormone ( PTH ) parathyroid hormonerelated peptid ( PTHrP ) Prior treatment bisphosphonates , fluoride , strontium within past five year treatment androgens , anabolic steroid , corticosteroid selective estrogen receptor modulators within past 12 month ( except hormone replacement therapy ) Prior treatment investigational drug within past 12 month History nephrolithiasis urolithiasis within past five year , history osteosarcoma time</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>BA058</keyword>
	<keyword>abaloparatide</keyword>
	<keyword>Abaloparatide-SC</keyword>
	<keyword>osteoporosis</keyword>
	<keyword>postmenopausal</keyword>
	<keyword>bone loss</keyword>
	<keyword>ACTIVE</keyword>
	<keyword>fracture</keyword>
</DOC>